Yang, Ning http://orcid.org/0000-0001-5121-7208
Wang, Yi http://orcid.org/0000-0002-4046-9511
Dai, Peihong
Li, Tuo http://orcid.org/0000-0001-6268-7520
Zierhut, Christian http://orcid.org/0000-0003-3501-603X
Tan, Adrian
Zhang, Tuo http://orcid.org/0000-0001-5396-918X
Xiang, Jenny Zhaoying
Ordureau, Alban http://orcid.org/0000-0002-4924-8520
Funabiki, Hironori http://orcid.org/0000-0003-4831-4087
Chen, Zhijian http://orcid.org/0000-0002-8475-8251
Deng, Liang http://orcid.org/0000-0002-8467-9342
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP180725)
IMVAQ Therapeutics (L.D.) MSK Technology Development fund (L.D) American Skin Association Research Scholar Award
Article History
Received: 2 June 2022
Accepted: 5 May 2023
First Online: 22 May 2023
Competing interests
: Memorial Sloan Kettering Cancer Center filed a patent application for the discovery of vaccinia viral inhibitors of the cytosolic DNA-sensing pathway and its use for improving MVA and vaccinia as oncolytic agents and vaccine vectors. The patent has been licensed to IMVAQ Therapeutics. L.D. and N.Y. are co-founders of IMVAQ Therapeutics. The remaining authors declare no competing interests.